A first-in-human trial of PRT12396 starts next month.
ApexOnco Front Page
Recent articles
Early data are coming with the KRAS G12D degrader ARV-806.
The company is starting four new pivotal trials this year.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company quietly deprioritises AlphaMedix.
Tecvayli and Hernexeos might get speedy approval decisions.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
RMC-5127 becomes the company’s fourth clinical project.
